Pfizer took several interim looks at the data during its vaccine trial, but it did not have enough infections in its test group to gain any meaningful data — until Sunday, Gupta reported. If anything, the data came earlier than expected: In October, Bourla made a comment ?in an open letter on Pfizer’s website, saying,?”Based on our current trial enrollment and dosing pace, we estimate we will reach this milestone in the third week of November.”
